MAUDE’S AWARDS 2026 RECIPIENTS   ...

Listen to or Subscribe...

#Alzheimer s and #Heart...

Researchers at Edith Cowan University’s (ECU) Centre for Precision Health have made a...

Hepatitis B Breakthrough: GSK's...

The US FDA has approved GSK's Hibsago for chronic hepatitis...

GSM, Ounces and What...

A hoodie’s weight is the weight of its fabric, usually listed as...
HomeSchizophrenia2 Schizophrenics React...

2 Schizophrenics React to Viral TikTok’s!


2 Schizophrenics React to Viral TikTok’s!

In this candid and compelling video, Schizophrenia advocate Michelle Hammer and comedian Dan Laitman, who lives with schizophrenia, openly discuss what it’s like to live with mental illness. Through personal stories and expert insights, they explore psychosis, hallucinations, and how psychiatry plays a role in managing schizophrenia.

Michelle and Dan bring together lived experience and psychological understanding—delving into how hallucinations manifest, what they feel like, and how they affect daily life. Alongside serious conversation, the video also features Michelle’s signature reaction-style commentary, giving viewers a layered, honest, and human look at mental health, stigma, and resilience.

Whether you’re curious about schizophrenia, interested in mental health advocacy, or seeking honest perspectives on inner experience, this discussion bridges the gap between science, lived reality, and hope.

VISIT YOUTUBE CHANNEL



Continue reading

MAUDE’S AWARDS 2026 RECIPIENTS    – Alzheimer’s Speaks

Listen to or Subscribe to the Alzheimer’s Speaks Podcast on Apple MAUDE’S AWARDS 2026 RECIPIENTS    Lori La Bey talks with Maude’s Awards, which was developed in 2019 to gather and share...

#Alzheimer s and #Heart Disease

Researchers at Edith Cowan University’s (ECU) Centre for Precision Health have made a groundbreaking discovery, revealing a significant genetic connection between Alzheimer’s disease (AD) and several coronary artery disease (CAD) related disorders. This research may offer new opportunities to...

Hepatitis B Breakthrough: GSK's New Drug Hibsago Helped 19% Stay Off Treatment

The US FDA has approved GSK's Hibsago for chronic hepatitis B, with 19% of trial participants achieving a functional cure.